on Berlin Heals Holding AG
Berlin Heals Launches C-MIC IV Heart Failure Trial
Berlin Heals Holding AG has initiated the C-MIC IV trial, an important step for its microcurrent therapy aimed at heart failure. Based in Zug, Switzerland, the company is conducting this international, randomized, double-blind, sham-controlled study to further assess the therapy's efficacy and safety. The trial follows the C-MIC III study's less invasive approach and will include 60 patients across six European countries.
The trial targets patients with symptomatic heart failure of either ischemic or non-ischemic origin, having a reduced ejection fraction above 20%. A novel aspect of this study is that all patients will have devices implanted, but will not know whether the therapy is active. The first patient was treated in Serbia, highlighting the trial's international scope.
John Brumfield, CEO, emphasized the trial's significance in building evidence for this innovative therapy. This effort aims to enhance the clinical understanding of microcurrent technology for heart failure.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Berlin Heals Holding AG news